Core Insights - Platinum Equity has entered into a definitive agreement to acquire the Products & Healthcare Services (P&HS) segment of Owens & Minor, with Owens & Minor retaining a 5% equity stake in the business [1][5]. Group 1: Company Overview - P&HS is a vertically-integrated medical supply distribution platform primarily serving the acute care market, recognized as a leading national distributor of medical and surgical supplies for hospitals and healthcare providers across the U.S. [2]. - Platinum Equity has a history of investing in healthcare and supply chain businesses, with 30 years of experience in acquiring and operating global businesses from large corporate entities [3][4]. Group 2: Strategic Intent and Market Dynamics - Platinum Equity aims to enhance P&HS's global capabilities to deliver essential products and services, leveraging its operational expertise and commitment to growth [3][4]. - The aging U.S. population and increasing demand for healthcare services are expected to drive sustainable long-term demand for medical supplies distribution, making the acquisition attractive for Platinum Equity [5]. Group 3: Transaction Details - The transaction is anticipated to close near the end of the year, pending regulatory review and customary closing conditions [5]. - Financial advisors for Platinum Equity include Bank of America and Fifth Third, while Citi and Wells Fargo are advising Owens & Minor [6].

Group 1: Earnings Performance - Eli Lilly reported quarterly earnings of $6.31 per share, exceeding the Zacks Consensus Estimate of $5.61 per share, and up from $3.92 per share a year ago, representing an earnings surprise of +12.48% [1] - The company posted revenues of $15.56 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.48%, compared to year-ago revenues of $11.3 billion [2] - Over the last four quarters, Eli Lilly has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Eli Lilly shares have declined approximately 3.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $6.22 on revenues of $15.74 billion, and for the current fiscal year, it is $22.05 on revenues of $60.43 billion [7] Group 3: Industry Context - The Large Cap Pharmaceuticals industry, to which Eli Lilly belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]